Transaction #25528 · Form 4 · 0001193125-25-335513
NewAmsterdam Pharma Co N.V. · Exercise / conversion · Ordinary Shares
NewAmsterdam Pharma Co N.V. · Transacted December 26, 2025 · Filed December 29, 2025
What does this filing report?
An SEC Form 4 filing for NewAmsterdam Pharma Co N.V. records an exercise / conversion involving Ordinary Shares on December 26, 2025. The reported quantity was 38,872. The filing date is December 29, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- NewAmsterdam Pharma Co N.V.
- Company CIK
- 0001936258
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 38,872
- Reported price
- 10
- Reference value
- 388,720
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 53,872
- Ownership description
- Not reported
- SEC acceptance time
- Dec 29, 2025, 5:14 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Kooij Louise Frederika ↗
Chief Accounting Officer
CIK 0002004379
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Filing footnotes & remarks
- F1
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.88 to $36.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F3
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.85 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F4
- The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.
- F5
- The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.